BCAB BioAtla Inc
Price (delayed)
$0.3395
Market cap
$19.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.44
Enterprise value
-$28.38M
BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms.
Highlights
BCAB's debt has shrunk by 66% YoY and by 33% QoQ
The company's EPS rose by 44% YoY and by 15% QoQ
BioAtla's quick ratio has increased by 16% QoQ but it has decreased by 14% YoY
The equity has dropped by 80% year-on-year and by 38% since the previous quarter
Key stats
What are the main financial stats of BCAB
Market
Valuations
Earnings
Shares outstanding
58.4M
Market cap
$19.83M
Enterprise value
-$28.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
1.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.58
Revenue
$11M
Gross profit
$11M
Operating income
-$73.94M
Net income
-$69.78M
EBIT
-$69.78M
EBITDA
-$68.85M
Free cash flow
-$71.94M
Per share
Balance sheet
Liquidity
EPS
-$1.44
EPS diluted
-$1.44
Free cash flow per share
-$1.48
Book value per share
$0.3
Revenue per share
$0.23
TBVPS
$1.08
Total assets
$52.42M
Total liabilities
$38.16M
Debt
$836,000
Equity
$14.27M
Working capital
$36.69M
Debt to equity
0.06
Current ratio
3.52
Quick ratio
3.37
Net debt/EBITDA
0.7
Margins
Efficiency
Dividend
EBITDA margin
-625.9%
Gross margin
100%
Net margin
-634.3%
Operating margin
-672.2%
Return on assets
-102.4%
Return on equity
-235.9%
Return on invested capital
N/A
Return on capital employed
-184.2%
Return on sales
-634.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCAB stock price
How has the BioAtla stock price performed over time
Intraday
-3.88%
1 week
-9.37%
1 month
4.21%
1 year
-90.36%
YTD
-42.57%
QTD
-2.1%
Financial performance
How have BioAtla's revenue and profit performed over time
Revenue
$11M
Gross profit
$11M
Operating income
-$73.94M
Net income
-$69.78M
Gross margin
100%
Net margin
-634.3%
BCAB's operating income is up by 43% YoY and by 14% from the previous quarter
BioAtla's net income has increased by 43% YoY and by 15% QoQ
BCAB's net margin is up by 15% QoQ
The operating margin has increased by 14% since the previous quarter
Growth
What is BioAtla's growth rate over time
Valuation
What is BioAtla stock price valuation
P/E
N/A
P/B
1.15
P/S
1.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.58
The company's EPS rose by 44% YoY and by 15% QoQ
The equity has dropped by 80% year-on-year and by 38% since the previous quarter
BCAB's P/B is 60% below its 5-year quarterly average of 3.0 and 57% below its last 4 quarters average of 2.8
Efficiency
How efficient is BioAtla business performance
The company's return on equity has shrunk by 113% YoY and by 26% QoQ
BioAtla's ROA has decreased by 36% YoY and by 6% from the previous quarter
The company's return on sales rose by 15% QoQ
Dividends
What is BCAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCAB.
Financial health
How did BioAtla financials performed over time
The company's total assets is 37% higher than its total liabilities
The company's total assets has shrunk by 56% YoY and by 16% QoQ
The total liabilities has declined by 22% year-on-year and by 2.8% since the previous quarter
BCAB's debt is 94% lower than its equity
BioAtla's debt to equity has surged by 100% YoY and by 20% QoQ
The equity has dropped by 80% year-on-year and by 38% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.